# Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)

> **NCT02615002** · PHASE2 · COMPLETED · sponsor: **Neurim Pharmaceuticals Ltd.** · enrollment: 371 (actual)

## Conditions studied

- Alzheimer's Disease

## Interventions

- **DRUG:** Piromelatine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02615002
- **Lead sponsor:** Neurim Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-11
- **Primary completion:** 2019-06
- **Final completion:** 2019-11-19
- **Target enrollment:** 371 (ACTUAL)
- **Last updated:** 2024-07-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02615002

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02615002, "Safety and Efficacy of Piromelatine in Mild Alzheimer's Disease Patients (ReCOGNITION)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02615002. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*